Galectin Therapeutics (GALT) Convertible Debt (2021 - 2026)

Galectin Therapeutics' Convertible Debt history runs 6 years deep, the most recent figure standing at $32.9 million for Q1 2026.

• In Q1 2026, Convertible Debt rose 204.06% year-over-year to $32.9 million; the TTM figure through Mar 2026 stood at $32.9 million (up 204.06% YoY), while the FY2025 annual figure was $32.7 million, up 204.69% from the prior year.
• Convertible Debt was $32.9 million for Q1 2026 at Galectin Therapeutics, up from $32.7 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $32.9 million in Q1 2026 to a low of $10.7 million in Q4 2024.
• Historically, Convertible Debt has averaged $27.7 million across 5 years, with a median of $30.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Convertible Debt jumped 205.96% in 2022, then sank 65.28% in 2025.
• A 5-year view of Convertible Debt shows it stood at $30.0 million in 2022, then grew by 3.13% to $30.9 million in 2023, then sank by 65.27% to $10.7 million in 2024, then soared by 204.69% to $32.7 million in 2025, then climbed by 0.54% to $32.9 million in 2026.
• The last three Convertible Debt figures came in at $32.9 million (Q1 2026), $32.7 million (Q4 2025), and $32.3 million (Q2 2025), per Business Quant data.